التفاصيل البيبلوغرافية
| العنوان: |
HIPEC as Up-Front Treatment in Locally Advanced Ovarian Cancer. |
| المؤلفون: |
Karanikas, Michail, Kofina, Konstantinia, Kyziridis, Dimitrios, Trypsianis, Grigorios, Kalakonas, Apostolos, Tentes, Antonios-Apostolos |
| المصدر: |
Cancers; Oct2024, Vol. 16 Issue 20, p3500, 14p |
| مصطلحات موضوعية: |
OVARIAN tumors, THERMOTHERAPY, TREATMENT effectiveness, CYTOREDUCTIVE surgery, RETROSPECTIVE studies, MULTIVARIATE analysis, DESCRIPTIVE statistics, CANCER patients, ADJUVANT chemotherapy, KAPLAN-Meier estimator, DISEASES, PERITONEAL cancer, MEDICAL records, ACQUISITION of data, PROGRESSION-free survival, DISEASE relapse, TUMORS, OVERALL survival, PROPORTIONAL hazards models |
| مستخلص: |
Simple Summary: This study evaluated the effect of hyperthermic intraperitoneal chemotherapy with complete or near-complete cytoreduction on naïve ovarian cancer women; 5- and 10-year overall survival, disease-specific survival, and disease-free survival rates were significantly higher in these patients. These patients were also 67% less likely to die from any cause, 75% less likely to die from cancer, and 46% less likely to develop recurrence compared to patients that were treated with cytoreductive surgery alone. These favorable results highlight the need for future randomized controlled trials in order to further determine the effect of hyperthermic intraperitoneal chemotherapy. Purpose: The main objective of the study is to evaluate the effect of hyperthermic intraperitoneal chemotherapy (HIPEC) in the treatment of naïve ovarian cancer women undergoing complete or near-complete cytoreduction by assessing the overall survival, the disease-specific survival, and the disease-free survival. The secondary objective is the identification of prognostic indicators of survival and recurrence of these patients. Patients—Methods: Retrospective study of treatment in naïve women with locally advanced ovarian cancer treated with cytoreductive surgery (CRS) and HIPEC and compared with those who were treated with cytoreduction alone. Clinicopathologic variables were correlated to overall survival, disease-specific survival, and disease-free survival using Kaplan–Meier method, and the multivariate Cox proportional hazards regression models. Results: 5- and 10-year overall survival, disease-specific survival, and disease-free survival rates were significantly higher in patients treated with CRS and HIPEC. These patients were 67% less likely to die from any cause (adjusted hazard ratio, aHR = 0.33, p = 0.001), 75% less likely to die from cancer (aHR = 0.25, p = 0.003), and 46% less likely to develop recurrence (aHR = 0.54, p = 0.041) compared to patients treated with CRS alone. Moreover, the poor performance status (aHR = 2.96, p < 0.001), the serous carcinomas (aHR = 0.14, p = 0.007), and the morbidity (aHR = 6.87, p < 0.001) were identified as independent indicators of poor overall survival. The degree of differentiation (aHR = 8.64, p = 0.003) was identified as the independent indicator of disease-specific survival (aHR = 4.13, p = 0.002), while the extent of peritoneal carcinomatosis (aHR = 2.32, p < 0.001) as the independent indicator of disease-free survival. Conclusions: Treatment in naïve patients with locally advanced ovarian cancer undergoing CRS plus HIPEC appears to have improved overall, disease-specific, and disease-free survival. [ABSTRACT FROM AUTHOR] |
|
Copyright of Cancers is the property of MDPI and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| قاعدة البيانات: |
Complementary Index |
Full Text Finder